Twenty years of anti-HER2 therapy-associated cardiotoxicity

Over the past 20 years, the prognosis of HER2-positive breast cancer has been transformed by the development of anti-HER2 targeted therapies. In early clinical trials of trastuzumab (ie, the first anti-HER2 agent to be developed) cardiotoxicity became a major concern. In the first published phase 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Pondé, Noam F, Lambertini, Matteo, de Azambuja, Evandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070246/
https://www.ncbi.nlm.nih.gov/pubmed/27843627
http://dx.doi.org/10.1136/esmoopen-2016-000073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070246/
https://www.ncbi.nlm.nih.gov/pubmed/27843627
http://dx.doi.org/10.1136/esmoopen-2016-000073

Ejemplares similares